Analysts Offer Predictions for Medpace FY2025 Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Medpace in a report issued on Thursday, October 23rd. Leerink Partnrs analyst M. Cherny now expects that the company will earn $14.70 per share for the year, up from their previous estimate of $14.14. The consensus estimate for Medpace’s current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace’s Q4 2025 earnings at $4.09 EPS.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS.

A number of other equities analysts have also commented on MEDP. Mizuho raised their price target on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a report on Friday. Robert W. Baird set a $613.00 price target on Medpace in a report on Friday. TD Cowen raised their price target on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a report on Friday. Rothschild Redb lowered Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medpace in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $475.90.

Medpace Price Performance

Medpace stock opened at $596.48 on Monday. Medpace has a one year low of $250.05 and a one year high of $625.00. The business has a fifty day moving average price of $505.80 and a 200-day moving average price of $394.74. The firm has a market capitalization of $16.80 billion, a P/E ratio of 41.71, a PEG ratio of 3.58 and a beta of 1.40.

Institutional Investors Weigh In On Medpace

Large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company’s stock valued at $94,000 after purchasing an additional 83 shares in the last quarter. Nordea Investment Management AB raised its position in Medpace by 4.8% during the second quarter. Nordea Investment Management AB now owns 61,125 shares of the company’s stock valued at $19,067,000 after purchasing an additional 2,792 shares in the last quarter. Inspire Investing LLC purchased a new stake in Medpace during the first quarter valued at about $2,059,000. Truist Financial Corp raised its position in Medpace by 10.2% during the second quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock valued at $4,048,000 after purchasing an additional 1,197 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Medpace by 10.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,182 shares of the company’s stock valued at $371,000 after purchasing an additional 111 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In related news, Director Cornelius P. Mccarthy III sold 1,662 shares of Medpace stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the sale, the director owned 10,197 shares of the company’s stock, valued at approximately $4,742,012.88. This trade represents a 14.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total value of $4,800,000.00. Following the sale, the vice president directly owned 57,500 shares of the company’s stock, valued at $27,600,000. This represents a 14.81% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 48,478 shares of company stock valued at $23,093,073. Company insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.